Shots:

• AbCellera reported that a second Ab from its collaboration with Lilly- LY-CoV1404 has entered clinical trials in patients with mild-to-moderate COVID-19. The program will join Lilly’s ongoing Blaze-4 study where it will be evaluated as monothx. and in combination with other mAbs
• AbCellera unveils the preclinical data demonstrating LY-CoV1404 binds to a rarely mutated region of the SARS-CoV-2 spike protein and neutralizes all currently known variants of concern
• In Mar’2020- AbCellera initially mobilized its pandemic response platform and discover the first mAb therapy- bamlanivimab for COVID-19 which FDA has authorized for emergency use

  Ref: Buisnesswire | Image: AbCellera